Study Uncovers Long-Sought Mechanism That Limits Centriole Duplication, With Implications For Potential Cancer Treatments
Main Category: Biology / BiochemistryAlso Included In: Cancer / Oncology; Genetics
Article Date: 27 Jan 2009 - 0:00 PDT
| Patient / Public: | ![]() | |
| Healthcare Prof: | ![]() |
Like DNA, centrioles need to duplicate only once per cell cycle. Rogers et al. uncover a long-sought mechanism that limits centriole copying, showing that it depends on the timely demolition of a protein that spurs the organelles' replication.
The study appears in the January 26, 2009 issue of the Journal of Cell Biology and online at http://www.jcb.org.
Centrioles start reproducing themselves during G1 or S phase. What prevents the organelles from xeroxing themselves again and again has puzzled researchers for more than a decade. The process could be analogous to the mechanism for controlling DNA replication. There, a licensing factor preps the DNA for duplication. During DNA synthesis, the factor gets tagged with ubiquitin molecules that prompt its destruction, thus preventing another round of copying.
To determine whether a similar mechanism keeps centrioles in check, Rogers et al. blocked Drosophila cells' production of different proteins that combine to form a ubiquitin-adding complex. Loss of one of these proteins, Slimb, allowed cells to fashion extra centrioles, the researchers found.
Slimb's target, the team showed, is the enzyme Plk4, which sports a Slimb-binding motif. Plk4 levels on the centrioles peaked during mitosis, and the enzyme vanished from the organelles by S phase. However, a mutant form of Plk4 that Slimb couldn't latch onto clung to the centrioles throughout the cell cycle and caused their over-duplication.
Plk4 serves as a licensing factor for centriole copying, Rogers et al. suggest. During mitosis, it sets the stage for the next cell division by phosphorylating an unidentified protein (or proteins) that will later instigate centriole duplication. Slimb and its protein partners then ubiquitinate Plk4, so that no enzyme remains on the centrioles by the time they are ready for copying. Thus, the organelles are duplicated once only. Tumor cells often bypass the limit on centriole duplication, and the work suggests that drugs to restrict the organelles' replication might hold promise as cancer treatments.
###
About the Journal of Cell Biology
Founded in 1955, the Journal of Cell Biology (JCB) is published by the Rockefeller University Press. All editorial decisions on manuscripts submitted are made by active scientists. JCB content is posted to PubMed Central, where it is available to the public for free six months after publication. Authors retain copyright of their published works and third parties may reuse the content for non-commercial purposes under a creative commons license. For more information, please visit http://www.jcb.org.
Rogers, G.C., et al. 2009. J. Cell Biol. doi:10.1083/jcb.200808049.
Source: Rita Sullivan
Rockefeller University Press
Visit our biology / biochemistry section for the latest news on this subject.
MLA
12 Feb. 2012. <http://www.medicalnewstoday.com/releases/136708.php>
APA
http://www.medicalnewstoday.com/releases/136708.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



